ENHERTU and pertuzumab approved in the US for 1st-line treatment of HER2+ metastatic breast cancer. FDA approves based on DESTINY-Breast09 Phase III trial results.
In Wilmington, Delaware, AstraZeneca and Daiichi Sankyo have received approval in the United States for their drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, confirmed by an FDA-approved test. This approval, following Priority Review and Breakthrough Therapy Designation by the FDA, is based on findings from the DESTINY-Breast09 Phase III trial.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments